LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Follicular Lymphoma, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 34-4 - June 26, 2020
- Editor: Jonathan W Friedberg
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 7 5 4 3 8 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 7 5 4 3 7 - 8
This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis issue of Hematology/Oncology Clinics, Guest Edited by Dr. Jonathan W. Friedberg, is devoted to Follicular Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Articles in this important issue include: Epidemiology of Follicular Lymphoma, Pathogenesis of Follicular Lymphoma, Circulating tumor DNA and MRD assessment in Follicular Lymphoma, Clinical and biological prognostic factors in Follicular Lymphoma, Vitamin D and Follicular Lymphoma, Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma, Initial Treatment of High Tumor Burden Follicular Lymphoma, Maintenance Antibody Therapy of Follicular Lymphoma, Cellular Therapy in Follicular Lymphoma, Immunomodulatory Agents in Follicular Lymphoma, Phosphoinositide 3-Kinase Inhibition in Follicular Lymphoma, Novel Agents Beyond Immunomodulatory Imide Drugs and Phosphoinositide 3-Kinases for Follicular Lymphoma, Early progression of Follicular Lymphoma, Biological Basis of Histological Transformation, and Treatment of Histological Transformation.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Hematology/Oncology Clinics of North America
- Preface
- Epidemiology of Follicular Lymphoma
- Key points
- Introduction
- Descriptive epidemiology
- Precursors
- Family history and genetic susceptibility
- Medical history risk factors
- Occupational and environmental risk factors
- Lifestyle and behavioral risk factors
- Insights from non-Hodgkin lymphoma subtype risk factor patterns
- Opportunities for prevention
- Summary and future directions
- Clinical and Biological Prognostic Factors in Follicular Lymphoma
- Key points
- Introduction
- Prognostic factors at initial diagnosis
- Prognostic factors during the course of treatment
- Risk factors for transformation
- Emerging prognostic factors
- Summary
- Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma
- Key points
- Introduction
- Definition of low tumor burden follicular lymphoma
- Studies in follicular lymphoma with limited-stage disease
- Management approaches to advanced-stage follicular lymphoma with limited tumor burden
- Summary and recommendations
- Initial Treatment of High Tumor Burden Follicular Lymphoma
- Key points
- What constitutes high tumor burden in patients with follicular lymphoma
- The optimal staging: to pet or not to pet?
- Initial treatment of high tumor burden follicular lymphoma: the choices
- Is there an optimal frontline chemotherapy?
- Special considerations: grade 3A and occult transformation
- The role of anti-CD20 monoclonal antibodies
- The pros and cons of lenalidomide-rituximab
- Post-therapy surveillance: can patients ever be discharged?
- Summary
- Antibody Therapy Maintenance in Follicular Lymphoma
- Key points
- Rationale for anti-CD20–BASED maintenance treatment
- Rituximab maintenance for low-tumor-burden advanced-stage follicular lymphoma
- Maintenance therapy or retreatment?
- Rituximab maintenance after rituximab chemotherapy
- Rituximab maintenance after autologous stem cell transplant
- Meta-analysis of the randomized studies
- Remaining open questions
- Summary
- Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy
- Key points
- Introduction
- Autologous stem cell transplantation in follicular lymphoma
- Allogeneic stem cell transplantation
- Adoptive cellular therapy: chimeric antigen receptor T cells
- Other emerging cellular immunotherapies
- Sequencing cellular therapies and future directions
- Immunomodulatory Agents in Follicular Lymphoma
- Key points
- Introduction
- Genomics in follicular lymphoma: switching off the immune rheostat
- Consequences of the perturbed immune rheostat: loss of immune synapse
- Heating up the rheostat in follicular lymphoma: override the inhibitory checkpoints
- IntIMiDation of follicular lymphoma cells: mechanisms of action of lenalidomide
- Two-hit counterstrike against follicular lymphoma cells: rationale for lenalidomide + antiCD20 combinations
- Building on lenalidomide + antiCD20 chemo-free backbone: targeting immune checkpoints
- A glimpse into the future: improving “synthetic” immune synapses with lenalidomide
- Summary
- Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma
- Key points
- Introduction
- Phosphatidylinositol-3-kinase background
- Approved agents
- Can we improve the safety of phosphatidylinositol-3-kinase inhibition?
- Reduced dosing strategies: maintaining efficacy while improving safety?
- Other agents in development
- Combinations in relapsed setting
- Studies in upfront setting
- Summary
- Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma
- Key points
- A population in need
- Mechanisms of lymphomagenesis and the tumor microenvironment
- Novel therapies
- Immune checkpoint inhibitors
- BCL-2 inhibitors
- Spleen tyrosine kinase and Janus kinase inhibitors
- Antibody–drug conjugates
- Radioimmunotherapy
- Bispecific antibodies
- Summary
- Early Progression of Follicular Lymphoma: Biology and Treatment
- Key points
- Introduction
- Early progressing follicular lymphoma
- Biology of early progressing follicular lymphoma
- Prognostic indices
- Management of early relapsed follicular lymphoma
- Summary
- The Biological Basis of Histologic Transformation
- Key points
- Introduction
- Definition
- Challenges in studying histologic transformation biology
- Recurrent genetic lesions associated with histologic transformation
- Clonal evolution
- Cell of origin classification and histologic transformation
- Role of the immune microenvironment
- Recent efforts in transformation prediction
- Summary
- Treatment of Histologic Transformation
- Key points
- Introduction
- Definition of histologic transformation
- Biology of transformation
- Incidence of transformation
- Risk factors for transformation
- Identifying histologic transformation
- Initial treatment and prognosis of histologic transformation
- Autologous stem cell transplant in the rituximab era
- Chimeric antigen receptor T-cell therapy
- Allogeneic transplant
- Targeted agents
- Future directions
- Summary
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 34-4
- Published: June 26, 2020
- Imprint: Elsevier
- Hardback ISBN: 9780323754385
- eBook ISBN: 9780323754378
JF
Jonathan W Friedberg
Affiliations and expertise
Professor, Department of Medicine, School of Medicine and Dentistry
Director, Cancer Center
Samuel E. Durand Chair in Medicine, School of Medicine and Dentistry
Professor, Cancer Center
University of Rochester Medical Center